Literature DB >> 16352304

Differential activation of ERK, p38, and JNK MAPK by nociceptin/orphanin FQ in the potentiation of prostaglandin cerebrovasoconstriction after brain injury.

William M Armstead1.   

Abstract

Fluid percussion brain injury elevates the cerebrospinal fluid (CSF) concentration of the opioid nociceptin/orphanin FQ (N/OFQ), which potentiates vasoconstriction to the prostaglandins U 46619, a thromboxane A(2) mimic, and prostaglandin (PG)F(2a). This study investigated the role of the extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) isoforms of mitogen activated protein kinase (MAPK) in potentiated prostaglandin vasoconstriction after brain injury and the relationship of brain injury induced release of N/OFQ to MAPK. Pial artery diameter was measured with a video microscaler by observation through a glass coverslip cranial window placed in the parietal cortex of newborn pigs. Brain injury potentiated U 46619 induced pial artery vasoconstriction but U 0126 and SB 203580 (10(-6) and 10(-5) M, respectively) (ERK and p38 MAPK inhibitors) blocked the potentiation. In contrast, administration of SP 600125 (10(-6) and 10(-5) M) (JNK MAPK inhibitor) only attenuated brain injury induced U 46619 potentiation and such responses were significantly different than that in the presence of either U 0126 or SB 203580 after FPI. Co-administration of N/OFQ (10(-10) M), the CSF concentration observed after brain injury, with U 46619 or PGF(2a) under non brain injury conditions potentiated prostaglandin vasoconstriction but U 0126 and SB 203580 blocked such potentiation. Administration of SP 600125 modestly attenuated prostaglandin potentiation by N/OFQ. These data show that activation of ERK and p38 primarily contribute to potentiation of prostaglandin constriction after brain injury. These data suggest that N/OFQ differentially activates ERK, p38, and JNK MAPK to contribute to potentiated prostaglandin vasoconstriction after fluid percussion brain injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352304     DOI: 10.1016/j.ejphar.2005.08.059

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Intraoperative Targeted Temperature Management in Acute Brain and Spinal Cord Injury.

Authors:  Jacqueline Kraft; Anna Karpenko; Fred Rincon
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 4.  Paradigm Shift in Materials for Skull Reconstruction Facilitated by Science and Technological Integration.

Authors:  Arushi Beri; Sweta G Pisulkar; Akansha V Bansod; Chinmayee Dahihandekar
Journal:  Cureus       Date:  2022-09-03

Review 5.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

6.  Catecholaminergic control of mitogen-activated protein kinase signaling in paraventricular neuroendocrine neurons in vivo and in vitro: a proposed role during glycemic challenges.

Authors:  Arshad M Khan; Todd A Ponzio; Graciela Sanchez-Watts; B Glenn Stanley; Glenn I Hatton; Alan G Watts
Journal:  J Neurosci       Date:  2007-07-04       Impact factor: 6.167

7.  Low cerebral blood flow is a non-invasive biomarker of neuroinflammation after repetitive mild traumatic brain injury.

Authors:  Sitara B Sankar; Alyssa F Pybus; Amanda Liew; Bharat Sanders; Kajol J Shah; Levi B Wood; Erin M Buckley
Journal:  Neurobiol Dis       Date:  2018-12-25       Impact factor: 5.996

8.  NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases.

Authors:  Elaine C Gavioli; Pedro R T Romão
Journal:  J Amino Acids       Date:  2011-11-17

9.  Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis.

Authors:  Velichka Pavlova; Elena Filipova; Katya Uzunova; Krassimir Kalinov; Toni Vekov
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2018       Impact factor: 2.895

10.  ERK and p38 contribute to the regulation of nociceptin and the nociceptin receptor in human peripheral blood leukocytes.

Authors:  Lan Zhang; Frank Stüber; Christoph Lippuner; Marcel Schiff; Ulrike M Stamer
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.